"According to the tests carried out at Rome's infectious-disease Spallanzani Hospital, an Italian coronavirus vaccine has antibodies generated in mice that work on human cells", Science Times reported. Llamas' antibodies are known for their ability to neutralize viruses, and when tested against the new coronavirus, proved effective in doing so once again, the study says.

Eight candidate vaccines have entered the human clinical trials and another 100 candidates are in preclinical evaluation to find a permanent cure for Coronavirus, the World Health Organisation (WHO) has said today.

Takis Biotech is the company developing the coronavirus vaccine candidate.

"This is not a competition".

So what is the progress in the vaccine? .

A team of Italian scientists has claimed to have developed a couple of vaccines that they claim neutralises the novel coronavirus in human cells.

"Vaccines have to be given a month or two before infection to provide protection", co-author Jason McLellan said in the statement.

Now, the scientists will be trying to gauge the longevity of the immunity response. Except for the DNA-based vaccine attempted by US-based Inovio Pharmaceuticals, all the other vaccines are now undergoing Phase 1 and Phase 2 human trials together, to fast track the development process. "Through electroporation, a vaccine can break into the cells and activate the immune system", the report adds.

A llama called Winter could prove useful in the hunt for a treatment for COVID-19, according to USA and Belgian scientists who have identified a tiny particle that appears to block the new coronavirus.

If successful, the antibodies would be particularly helpful for our most vulnerable members of society such as the elderly and immunocompromised. The scientists are expecting better results after the second vaccination and it is also believed that if the new vaccine works, it could help in preventing any COVID-19 evolution and its possible mutations.

Earlier on March 28, Russian Federation had claimed it had created a drug, based on the antimalarial Mefloquine, to treat patients suffering from the coronavirus disease.

The Russian authorities announced developing the drug as global virus tally crossed 600,000 confirmed patients and almost 30,000 deaths.



Source link